Hypercholesterolemia is escalating as a critical public health challenge across China, with recent data revealing a stark rise in cardiovascular mortality linked to elevated low-density lipoprotein cholesterol (LDL-C). A study published in the Journal of the American College of Cardiology reported that between 2010 and 2020, LDL-C–associated deaths increased by 34.41%, while total attributable deaths surged by 94.02%. These figures underscore an urgent need for more effective, individualized lipid-lowering strategies—particularly among high- and very-high-risk patients with established atherosclerotic cardiovascular disease (ASCVD), diabetes, or multiple risk factors.
Against this backdrop, clinicians and patients alike are increasingly evaluating combination therapy—specifically, the pairing of atorvastatin calcium (marketed as Lipitor®) and the novel, domestically developed cholesterol absorption inhibitor hetrombopag (brand name Saishimei®). Understanding how these agents differ—and why their synergy represents a paradigm shift in lipid management—is essential for optimizing long-term cardiovascular outcomes.
Atorvastatin, a cornerstone statin, works by competitively inhibiting hepatic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase—the rate-limiting enzyme in cholesterol biosynthesis. By suppressing de novo cholesterol production in the liver, it upregulates LDL receptors on hepatocytes, enhancing clearance of circulating LDL-C. In contrast, hetrombopag selectively targets Niemann-Pick C1-like 1 (NPC1L1) protein in the jejunal brush border, thereby blocking intestinal absorption of both dietary and biliary cholesterol. This dual-pathway intervention—reducing synthesis *and* limiting absorption—addresses two fundamental drivers of hypercholesterolemia in a complementary, non-overlapping manner.
The 2024 Chinese Guidelines for Lipid Management set stringent LDL-C targets: <1.8 mmol/L (with ≥50% reduction from baseline) for very-high-risk patients, and <1.4 mmol/L (also ≥50% reduction) for ultra-high-risk individuals—including those with prior myocardial infarction, ischemic stroke, or diabetes plus additional risk factors. Yet clinical reality often falls short: many patients fail to reach these goals on moderate-intensity statin monotherapy. Escalating statin doses carries diminishing returns and increases risks—including transaminase elevation, myopathy, and new-onset type 2 diabetes. Hetrombopag offers a compelling alternative: phase III clinical trials demonstrate that its addition to atorvastatin yields an *additional* ~16% LDL-C reduction beyond statin monotherapy—translating into significantly higher rates of guideline-directed goal attainment and greater potential for plaque stabilization and regression.
Safety is equally pivotal in chronic disease management. Notably, hetrombopag exhibits a favorable tolerability profile when combined with statins. Pooled analyses from pivotal trials confirm no increased incidence of statin-associated adverse events—including hepatotoxicity, myalgia, or renal impairment—when hetrombopag is added. Pharmacokinetically, hetrombopag undergoes balanced hepatic and renal elimination, with an overall systemic clearance exceeding 93%. As a result, dose adjustment is unnecessary in patients with mild-to-moderate hepatic impairment or chronic kidney disease—a distinct advantage for older adults and those with comorbidities commonly seen in ASCVD populations.
Guideline endorsement now reflects this evolving evidence base. The 2023 Chinese Guidelines for Lipid Management explicitly recommend statin–cholesterol absorption inhibitor combinations for patients with diabetes and established ASCVD, citing enhanced cardiovascular benefit. Similarly, the 2024 Chinese Expert Consensus on Lipid Management in Patients with Diabetes advocates initiating combination therapy—moderate-intensity statin plus hetrombopag—as first-line treatment for very-high-risk diabetic patients requiring ≥50% LDL-C reduction. This represents a strategic move toward early, intensive, and sustainable lipid control.
In summary, the question “Which is better—hetrombopag or atorvastatin?” misframes the issue. Neither agent supplants the other; rather, their mechanistic synergy defines a new standard of care. For patients struggling to meet aggressive LDL-C targets—or those at heightened risk of statin-related toxicity—combination therapy delivers superior efficacy without compromising safety. Ultimately, optimal lipid management remains rooted in shared decision-making: clinicians must tailor regimens to individual risk profiles, comorbidities, and pharmacokinetic considerations—ensuring that cardiovascular protection is not just achieved, but sustained.